Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
ION363 Phase 3 Results Expected
ION363 • Amyotrophic Lateral Sclerosis
Target Indication
Amyotrophic Lateral Sclerosis
Clinical Trial
Last updated: 12/4/2025
IONS
Ionis Pharmaceuticals, Inc.